23-Jan-2026
CooperCompanies to Present at the J.P. Morgan Healthcare Conference
Globe Newswire (Mon, 29-Dec 4:15 PM ET)
CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors
Globe Newswire (Tue, 23-Dec 8:00 AM ET)
Market Chameleon (Fri, 5-Dec 6:12 AM ET)
CooperCompanies Announces New Chair of the Board and Strategic Review
Globe Newswire (Thu, 4-Dec 4:20 PM ET)
CooperCompanies Announces Fourth Quarter and Full Year 2025 Results
Globe Newswire (Thu, 4-Dec 4:15 PM ET)
Browning West Delivers Letter to The Cooper Companies Board of Directors
Globe Newswire (Wed, 19-Nov 8:45 AM ET)
CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025
Globe Newswire (Tue, 4-Nov 4:15 PM ET)
Market Chameleon (Thu, 18-Sep 5:08 AM ET)
Market Chameleon (Wed, 17-Sep 12:50 PM ET)
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Cooper Companies trades on the NASDAQ stock market under the symbol COO.
As of January 23, 2026, COO stock price declined to $81.29 with 1,352,498 million shares trading.
COO has a beta of 0.91, meaning it tends to be less sensitive to market movements. COO has a correlation of 0.25 to the broad based SPY ETF.
COO has a market cap of $15.93 billion. This is considered a Large Cap stock.
Last quarter Cooper Companies reported $1 billion in Revenue and $1.15 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.04.
In the last 3 years, COO traded as high as $112.38 and as low as $61.78.
The top ETF exchange traded funds that COO belongs to (by Net Assets): VTI, VOO, VB, VBR, IVV.
COO has underperformed the market in the last year with a price return of -15.0% while the SPY ETF gained +14.2%. However, in the short term, COO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.1% vs +2.9% return in SPY. But in the last 2 weeks, COO shares have been beat by the market, returning -2.6% compared to an SPY return of -0.7%.
COO support price is $81.72 and resistance is $83.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COO shares will trade within this expected range on the day.